表紙
市場調查報告書

α1anti胰蛋白酶缺損症 (A1AD):開發中產品分析

Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 919376
出版日期 內容資訊 英文 106 Pages
訂單完成後即時交付
價格
α1anti胰蛋白酶缺損症 (A1AD):開發中產品分析 Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 106 Pages
簡介

本報告提供全球各國α1anti胰蛋白酶缺損症 (A1AD)的開發中產品的開發情形相關分析,開發中產品的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業的簡介,主要藥物概要,最新的產業趨勢等調查。

簡介

  • 調查範圍

α1anti胰蛋白酶缺損症 (A1AD) - 概要

α1anti胰蛋白酶缺損症 (A1AD) - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學、研究機關的開發平台趨勢
  • 企業開發中的產品
  • 在大學、研究機關開發中的產品

α1anti胰蛋白酶缺損症 (A1AD) - 治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發α1anti胰蛋白酶缺損症 (A1AD)的治療藥的企業

  • Adverum Biotechnologies Inc
  • Alnylam Pharmaceuticals Inc
  • Apic Bio Inc
  • Applied Genetic Technologies Corp
  • Arrowhead Pharmaceuticals Inc
  • AstraZeneca Plc
  • Beam Therapeutics Inc
  • Editas Medicine Inc
  • Evolve Biologics Inc
  • Grifols SA
  • Inhibrx Inc
  • Intellia Therapeutics Inc
  • International Stem Cell Corp
  • Kamada Ltd
  • LEXEO Therapeutics LLC
  • Liminal BioSciences Inc
  • Logicbio Therapeutics Inc
  • PlantForm Corp
  • Promethera Biosciences SA
  • Renovion Inc
  • Santhera Pharmaceuticals Holding AG
  • Trucode Gene Repair Inc
  • Vertex Pharmaceuticals Inc
  • Z Factor Ltd

α1anti胰蛋白酶缺損症 (A1AD) - 治療藥的評估

α1anti胰蛋白酶缺損症 (A1AD) - 暫停中的計劃

α1anti胰蛋白酶缺損症 (A1AD) - 開發中止的產品

α1anti胰蛋白酶缺損症 (A1AD) - 產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11993IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H1 2020, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) pipeline landscape.

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 4, 3, 14, 3 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alpha-1 Antitrypsin Deficiency (A1AD) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Alpha-1 Antitrypsin Deficiency (A1AD) - Overview
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Development
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Therapeutics Assessment
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Companies Involved in Therapeutics Development
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Drug Profiles
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Adverum Biotechnologies Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Alnylam Pharmaceuticals Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Apic Bio Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Applied Genetic Technologies Corp, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Arrowhead Pharmaceuticals Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Beam Therapeutics Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Editas Medicine Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Evolve Biologics Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Grifols SA, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Inhibrx Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Intellia Therapeutics Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by International Stem Cell Corp, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Kamada Ltd, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by LEXEO Therapeutics LLC, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Liminal BioSciences Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Logicbio Therapeutics Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Mereo Biopharma Group Plc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by pH Pharma Co Ltd, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by PlantForm Corp, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Promethera Biosciences SA, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Renovion Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Santhera Pharmaceuticals Holding AG, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Trucode Gene Repair Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Vertex Pharmaceuticals Inc, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Pipeline by Z Factor Ltd, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Dormant Projects, H1 2020
  • Alpha-1 Antitrypsin Deficiency (A1AD) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Alpha-1 Antitrypsin Deficiency (A1AD), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020